title: The effect of Olanzapine and Sertraline on personality disorder in patients with methadone maintenance therapy.
abstract: BACKGROUND
  Various drugs have been suggested for treatment of Borderline Personality Disorder (BPD)-a disabling disease affecting two percent of the general population. If a drug could alleviate a wide range of symptoms, it would be more suitable. In these disorders drug addiction is very common. This fact makes the symptoms complicated and the treatment more difficult.
  
  
  METHODS
  This study is designed to evaluate the effect of Olanzapine and Sertraline in patients suffering from personality disorders who are on methadone maintenance therapy. This study is a clinical trial. 120 males and females were chosen for methadone maintenance therapy through interview by a psychiatrist based on DSM-IV-TR diagnostic criteria for BPD. Afterwards they were randomly divided into two groups. These groups separately received Olanzapine (5-10 mg daily) and Sertraline (50-100 mg daily) therapy. The SCL-90 questionnaire was filled by all participants before treatment and at the 4th, 8th and 12th weeks of treatment.
  
  
  RESULTS
  According to this clinical trial, Olanzapine and Sertraline are effective in ameliorating symptoms of depression, anxiety and aggression, reducing sensitivity in interpersonal relationships and alleviating obsessive symptoms, pessimistic behaviors and somatization disorders in patients with personality disorders on methadone maintenance therapy.
  
  
  CONCLUSIONS
  As result of this study it appears that Olanzapine and Sertraline are definitely effective in alleviating symptoms of patients with personality disorder, prescribing theses drugs are recommended for these patients.
authors.affiliation: Lorestan University of Medical Sciences, Tehran, Iran. swt_f@yahoo.com
authors.forename: Mojhgan
authors.initials: M
authors.lastname: Jariani
authors.forename: Mandana
authors.initials: M
authors.lastname: Saaki
authors.forename: Hedayat
authors.initials: H
authors.lastname: Nazari
authors.forename: Mehdi
authors.initials: M
authors.lastname: Birjandi
mesh_terms: D000328:Adult; D000374:Aggression / Q000187:drug effects; D000701:Analgesics, Opioid / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy / Q000523:psychology; D001569:Benzodiazepines / Q000627:therapeutic use*; D001883:Borderline Personality Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology*; D003863:Depression / Q000188:drug therapy / Q000523:psychology; D039721:Diagnostic and Statistical Manual of Mental Disorders; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007398:Interpersonal Relations; D008297:Male; D008691:Methadone / Q000627:therapeutic use*; D009770:Obsessive Behavior / Q000188:drug therapy / Q000523:psychology; D000077152:Olanzapine; D012494:Sampling Studies; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D020280:Sertraline / Q000627:therapeutic use*; D012720:Severity of Illness Index; D013001:Somatoform Disorders / Q000188:drug therapy / Q000523:psychology; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D000701:Analgesics, Opioid; D001569:Benzodiazepines; D008691:Methadone; D000077152:Olanzapine; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline